Overview

A Study LY2228820 for Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Carboplatin
Gemcitabine